

THE 12<sup>th</sup> ANNUAL  
**BIOLOGICS**  
MANUFACTURING ASIA 2025

9<sup>th</sup> Edition  
**BIOLOGISTICS**  
WORLD ASIA 2025

**ADC ASIA**  
CONGRESS 2025

 **Biologics**  
**Digitalization & AI**  
World 2025

 **3<sup>RD</sup>**  
**CLINICAL TRIALS**  
FESTIVAL ASIA 2025

# COMBINE AGENDA

12th - 13th March 2025 | Sands Expo & Convention Centre, Singapore

| Time    |   |  |    |    |    |   |
|---------|--|--|--|---|---|--|
|         | Track 1  | Track 2  |  |   |   |  |
| 8.50 AM | IMAPAC Opening Remarks   | IMAPAC Opening Remarks   | IMAPAC Opening Remarks   | IMAPAC Opening Remarks  |   | IMAPAC Opening Remarks   |
| 8.55 AM | Chairman Opening Remarks   | Chairman Opening Remarks   | Chairman Opening Remarks<br>Pankaj Thakur, General Manager, Hetero, India  | Chairman Opening Remarks  | Chairman Opening Remarks  | Chairman Opening Remarks<br>Ben Ayers, Vice President, Antibody-Drug Conjugates, Hummingbird Bioscience, Singapore   |
|         | <b>Asia's Biologics Manufacturing Revolution</b><br>Embracing Global Trends and Seizing the Opportunities  | <b>Analytical Development and Product Characterization</b><br>Emerging Technologies for Process Control  | <b>End-to-End Supply Chain Management Best Practices</b>   | <b>Advancement in APAC as The Global Clinical Trials Hub</b>  | <b>AI &amp; Digitalisation in Biopharma</b><br>Current Landscape, Emerging Challenges & Future Horizons   | <b>Industry Outlook: Innovations in ADC Development</b><br>Advancements in Antibody Selection, Linker Technologies and Payload Design  |
| 9.00 AM | <b>Keynote: Quo Vadis Biopharma Manufacturing? – A Review of the Ongoing Paradigm Shift in Biopharma Manufacturing and Outlook to the Future</b><br>Uwe Buecheler, Independent Advisor & Former Business Unit Head, Biopharma, Boehringer Ingelheim, Germany | <b>Innovative Analytical Approaches for CMC Developments in New Molecular</b><br>Dr. Sanjay Niranjana, Assistant Director, Biossay Development, Lupin, India                             | <b>Panel Discussion: Building Resilient Supply Chains for Continuous Production</b><br>Moderator: Raymon Krishnan, President, The Logistics and Supply Chain Management Society, Singapore<br>Panelists:<br>● David Wee, Regional Cargo Manager, Asia Pacific, IATA, Singapore<br>● Jeffrey Tan, President, Singapore Computer Society (SCS) Supply Chain Management (SCM) Chapter, Singapore<br>● Namita Arora, Senior Specialist Supply Chain Planning, MSD, Singapore<br>● Oscar Sanchez Salina, Area Lead Logistics & Distribution, Asia North, AstraZeneca, Singapore | <b>Panel Discussion: The Global Clinical Trials Landscape in the APAC Region in the Next 3 Years</b><br>Moderator: Michelle Dee, Director, Asia Pacific Field Medical Centre of Excellence, Global Scientific & Value Content and Medical Information, MSD, Singapore<br>● Panelist 1: Prof. Danny Soon, CEO of Consortium for Clinical Research and Innovation Singapore, Executive Director of Singapore Clinical Research Institute, Interim Executive Director of Advanced Cell Therapy and Research Institute Singapore<br>● Panelist 2: Suhail Ali, Vice President & Regional Head, APAC Clinical Delivery and Project Management, ICON Plc, Singapore<br>● Panelist 3: Indri Rooslamati, Acting Director, National Biomedical Genome | <b>Panel Discussion Topic: Harnessing AI and Digital Transformation in Biopharma: Challenges, Opportunities, and the Path Forward</b><br>Moderator: Whang Yihang, Regional Director, Essex Bio-Technology, Singapore<br>Panelists:<br>● Kamyar Sadri, Senior Digital, Data & IT Manager, Novo Nordisk, Singapore<br>● Syifa Mutiara Hersista, AI and Machine Learning Manager, PT Bio Farma, Indonesia<br>● Alvin Chan Guo Wei, Assistant Professor, Nanyang Technological University, Singapore<br>● Adam Chee, Founding Lead, Centre for AI-Enabled Health (CAIEH), Singapore | <b>Optimizing the Design of Next Generation ADCs for Oncology</b><br>Paul Moore, PhD, Chief Scientific Officer, Zymeworks, USA   |
| 9.25 AM | <b>Polysorbate Degradation challenges and Risk mitigation strategies</b><br>Hemasunder Reddy, Director, APAC, Pfanstiehl, Singapore  | <b>Setting Specification for Batch Release in Different Stages of Biologics Development</b><br>Assist Prof. Wisit Tangkeangsrisin, Deputy Director, National Vaccine Institute, Thailand |  |   |   | <b>Accelerate Bioconjugate Development with WuXi XDC's Fully Integrated Capabilities and Expanding Global Capacity</b><br>Dr. Jun Hu, Head of Client Enabling Center of Excellence & Head of Singapore Site Management, WuXi XDC |

|          |   |  |  |  |   |   |
|----------|---|--|--|--|---|---|
| 9.40 AM  |   |  | <p><b>Optimising BioPharma Logistics: Emerging Global Trends &amp; Opportunities</b></p> <p><b>Ken McMahon</b>, Managing Director of Customer Solutions &amp; Special Services (SpS), <b>FedEx Express Asia-Pacific, Middle East, and Africa</b></p> | <p>Science Institute and Clinical Research Center (INA-CRC), <b>Ministry of Health of Republic Indonesia</b></p> <ul style="list-style-type: none"> <li>● <b>Panelist 4: Dr. Pankaj Thakur</b>, Senior General Manager, Head Clinical Trials Project Management, <b>Clinical Development and Medical Affairs (CD&amp;Ma)</b>, Hetero Group of Pharma, India</li> </ul> |   |   |
| 9.45 AM  |   |  |  |  | <p><b>AI In Drug Discovery and Development – Advanced Therapies</b></p> <p><b>Beyond Algorithms: Harnessing Data Quality for AI-Driven Drug Discovery</b></p>   |   |
| 9.50 AM  | <p><b>Navigating an Increasingly Volatile World: Biopharma's Path to Future-Readiness</b></p> <p><b>Wolfram Carius</b>, Executive Vice President, Cell &amp; Gene Therapy, <b>Bayer, Germany</b></p>  | <p>Reserved for <b>Nur Amalia Limeilati, M.Si</b>, Research Manager Routine Analysis and Validation, <b>PT Biofarma</b></p>  |  | <p><b>Advancing Phase 1 Clinical Trials in India: Opportunities, Challenges and insights on ICMR CAR Networks</b></p> <p><b>Speaker: Dr Satyajit Mohapatra</b>, Director, Centre for Clinical Trials and Research, <b>SRM MCH&amp;RC, SRM IST, India</b></p>   | <p><b>Wilson Goh Wen Bin</b>, Chief Data Scientist, Centre of AI in Medicine, <b>Nanyang Technological University, Singapore</b></p>  | <p><b>Plant-Derived Immunocytokines: A Next Generation Anticancer Therapy Combining Checkpoint Inhibitors and Cytokine</b></p> <p><b>Waranyoo Phoolcharoen</b>, Chief Technical Officer and Co-Founder, <b>Baiya Phytopharm, Thailand</b></p> |
| 10.05 AM |   |  |  | <p><b>Accelerating Clinical Trials in Indonesia: Challenges and Opportunities</b></p>  |   |   |
| 10.10 AM |   |  | <p><b>IATA Standards and Recommended Practices for Air Cargo Pharmaceutical Handling</b></p> <p><b>David Wee</b>, Regional Cargo Manager, Asia Pacific, <b>IATA, Singapore</b></p>   | <p><b>Indri Rooslamati</b>, Director, National Biomedical Genome Science Institute and Clinical Research Center (INA-CRC), <b>Ministry of Health, Indonesia</b></p>  | <p><b>Leveraging AI for Breakthrough Solutions in Drug Discovery and Development</b></p> <p><b>Asad Abu Bakar Ali</b>, Director, Biomarkers and Data Analytics, <b>MSD, Singapore</b></p>   | <p><b>Morning Tea Break, Exhibition Viewing &amp; 1-1 Attendee Networking</b></p>   |
| 10.15 AM | <p><b>Morning Tea Break, Exhibition Viewing &amp; 1-1 Attendee Networking</b></p>   | <p><b>Morning Tea Break, Exhibition Viewing &amp; 1-1 Attendee Networking</b></p>  |  |  |   |   |
| 10.35 AM |   |  |  |  |   |   |
| 10.40 AM |   |  |  |  |   |   |
| 11.00 AM | <p><b>Upstream Processing</b></p> <p><b>Breakthrough in Cell Line Development &amp; Engineering</b></p> <p><b>End-to-End Lifecycle Management of New Biologics for IND Submission: CDMO's Role in Optimizing Developability and Manufacturability for Clinical Advancement</b></p> <p><b>Amit Jogi</b>, Head, CDMO, Biologics, <b>Aurigene Pharmaceutical Services, India</b></p> | <p><b>Analytics &amp; Quality</b></p> <p><b>In-process Analytics &amp; Product Quality Monitoring</b></p> <p><b>Strategies for Robust Commercial Manufacturing Network of Biologics (TBC)</b></p> <p><b>Yuan Wen</b>, Vice President, Global Manufacturing Business Unit, <b>WuXi Biologics, China</b></p> | <p><b>Morning Tea Break, Exhibition &amp; Poster Presentation Viewing, 1-1 Networking</b></p>  |  | <p><b>Early-Stage R&amp;D of Antibody Drug Conjugates (ADCs)</b></p> <p><b>Characterization, Analysis and Molecule Design</b></p> <p><b>Innovations in Next-Generation Glycosite-Specific ADCs</b></p> <p><b>Dr. Chung-Yi Wu</b>, President, CEO, <b>CHO Pharma, Taiwan</b></p> | <p><b>Morning Tea Break &amp; Exhibition Viewing &amp; 1-1 Networking Meeting</b></p>   |



|          |   |  |  |   |   |  |  |
|----------|---|--|--|---|---|--|--|
| 12.45 PM |   |  |  |   |   |  |  |
| 1.50 PM  |   |  |  |   |   |  |  |
| 2.00 PM  |   |  |  |   |   |  |  |
| 2.15 PM  | Upstream Processing<br>Advances in Cell Culture Media Development & Raw Material Qualification  | Analytics & Quality<br>In-process Analytics & Product Quality Monitoring   | Strengthening Last Mile Distribution for Cold Chain Resilience   | Standards Resilience: Securing Supply Chain and Brands  | Transforming Clinical Trials through Biomarker Advancements   | Next Gen Biomanufacturing – Optimizing Cost, Quality & Efficiency  | Lunch Break, Exhibition Viewing & 1-1 Attendee Networking  |
|          | 2.30 PM   | Novel, non-traditional antibacterials: Therapeutic protein antibiotic targeting drug-resistant <i>Klebsiella Pneumoniae</i><br>Sukumar Hariharan, Head, Development, Gangagen Biotechnologies, India | Ensuring Vaccine Quality: Navigating the Landscape of GxP Quality Management Systems<br>Tobin Guarnacci, Global Head Quality Management, IVI, Thailand | Significance of Cold Chain Management in Cell Therapy<br>Arun Prasath, Director, Singapore Cord Blood Bank, Singapore | Harnessing Drug Target / Biomarker Identification to Accelerate Precision Therapies into the Clinic<br>Michael Winther, Senior Director, Target Discovery, Engine Biosciences Pte Ltd, Singapore  | Harnessing Machine Learning for Process Optimisation<br>Syifa Mutiara Hersista, AI and Machine Learning Manager, PT Bio Farma, Indonesia                                   |  |
| 2.40 PM  | Accelerate Biological Drug Submission in the Combinational Product Development Journey<br>Julia Zhu, Technical Services Manager, Greater Asia, BD, Singapore                | Emerging Technologies and Applications<br>Novel Therapeutics Modalities<br>Journey of a Novel First-In-Class Checkpoint Ab<br>Ashvini Kumar Dubey, Principal Scientist, Zumutor Biologics, India     |  |   | Use of Advanced Brain Imaging Biomarkers in Advancing Therapeutics in Stroke Management<br>Prof. Mark Parsons, Director of Academic and Industry Partnerships, Research and Innovation, Hunter New England Local Health District, Australia | Digital Supply Chain – Improving Agility & Efficiency  | Process Development & Optimization Intensifying Monoclonal Antibody Process for Higher Yields and Faster Time-to-Market<br>Site-specific Conjugation in ADC Development<br>Simon Shih-Hsien Chuang, CEO, Honeybear Biosciences, Taiwan |
| 2.55 PM  |   |  |  |   |   |  |  |
| 3.00 PM  |   |  |  |   |   |  |  |
| 3.05 PM  | Technological Innovation Drives Advancements in Upstream Bioprocessing<br>Hang Zhou, Senior Vice President & Head, Bioprocess Research & Development, WuXi Biologics, China | mRNA-based single-domain antibodies<br>Shawn Seong, Chief Executive Officer, Shaperon Inc., Korea  | Afternoon Break, Exhibition & Poster Presentation Viewing, 1-1 Networking  |   | Leveraging Mobile Technology in Clinical trials: Wearables and Digital Endpoint Strategy and Validation<br>Suhail Ali, Vice President & Regional Head, APAC Clinical Delivery and Project Management, ICON Plc, Singapore                   | Achieving Greater Agility in Supply Chains Through Automation and Robotics<br>Sahaf Ibrahim, Supply Chain Business Partner, Sanofi, Singapore                              | CMC development consideration for next generation ADCs<br>Gary Khoo, Vice President CMC, Hummingbird Bioscience, Singapore   |
|          |   |  |  |   |   | Building a Strong Data Strategy: The Foundation for AI-Driven Digital Transformation<br>Srikant Vinakota, Former Associate Director - End2End Analytics, Kenvue, Singapore |  |



|         |   |   |  |  |   |  |
|---------|---|---|--|--|---|--|
| 5.05 PM |   | <b>Bioprocessing 4.0: Digital Transformation in Process Development</b>   |  | <b>From Data to Decisions: The Power of Pharmacometrics in Drug Development</b>  | <b>Bora Kim</b> , Former Sr Digital Technology and Innovation Manager, <b>Amgen</b> , Singapore |  |
|         | <b>Adopting the Best Practices for Achieving Highest Titer and Best Match for mAb Biosimilars</b>   | CSL R&D Digital Ecosystem<br><br>Dominik Schneider, Senior Manager, R&D Enabling Technology, <b>CSL Behring</b> , Germany |  | <b>Dr. Cheng Cai Tang</b> , Director Clinical Pharmacology, Modeling and Simulation (CPMS), <b>Parexel International</b> , Singapore |   |  |
| 5.15 PM | <b>Sanjeev, Gupta</b> , Senior Vice President & Head, Biosimilars, <b>Ipca Laboratories</b> , India |   |  | <b>Clinical Trials and Medical Affairs: Exploring Synergies and Collaboration Opportunities in the Age of AI</b>                     | END OF CONFERENCE   |  |
| 5.30 PM | Chairperson Closing Remarks   | Chairperson Closing Remarks   |  | <b>Romik Ghosh</b> , Director, Medical Affairs, <b>Novo Nordisk</b> , India  |   |  |
| 5.40 PM |   |   |  | END OF CONFERENCE DAY 1  |   |  |
| 5.45 PM | END OF CONFERENCE DAY 1   |   |  |  |   |  |
| 6.00 PM | Asia-Pacific Biopharma Excellence Gala Dinner Awards 2025   |   | Clinical Trials Excellence Awards 2025 | Asia-Pacific Biopharma Excellence Gala Dinner Awards 2025  | Asia-Pacific Biopharma Excellence Gala Dinner Awards 2025                                       |  |

| Time     |   |    |    |   |
|----------|--|--|---|--|
|          | Track 1  | Track 2  |   |  |
| 8.50 AM  | IMAPAC Opening Remarks   | IMAPAC Opening Remarks   |   | IMAPAC Opening Remarks   |
| 8.55 AM  | Chairman Opening Remarks   | <b>Chairman Opening Remarks</b><br>Xenia Sango, Chief Executive Officer & Managing Director, VivaZome Therapeutics, Australia  | Chairman Opening Remarks  | Chairman Opening Remarks   |
|          | <b>Downstream Processing</b><br>Advances in Product Concentration and Purification by Chromatography   | Tech Transfer & Scale-Up Strategy  | Harnessing Digital Transformation in Bio-Pharma Logistics   | Advancing Pre-Clinical Research: From Discovery to Clinical Trials   |
| 9.00 AM  | <b>Toolbox Strategy for Bispecific Antibody Purification</b><br>Zhang Wei, Principal Scientist & Group Leader, DSP, Bioprocessing Technology Institute, A*STAR, Singapore      | <b>Strategic Scale-Up of Egg-Based Vaccine Technology: From Innovation to Commercial Production</b><br>Dr. Somchaiya Surichan, Director of Vaccine and Biological Production Plant, GPO, Thailand  | <b>Panel Discussion: Technological Advancements for Enhanced Cold Chain Efficiency</b><br><br>Moderated by:<br>Tam C. Nguyen, Deputy Director of Research, St Vincent's Hospital Melbourne, Australia<br>Panellists:<br><ul style="list-style-type: none"> <li>Shawn Lim, Asia Artwork Mgmt + Lead of Strategic Projects, Santen Pharmaceutical, Singapore</li> <li>Brajesh Karjee, Pharmaceutical Supply Chain and Strategic Sourcing Professional, Singapore</li> <li>Pradip Gyanwali, Chief Executive, Nepal Health Research Council, Nepal</li> </ul> | <b>Advancing Pre-Clinical Research: Integrating Discovery, POC, and Safety Studies for Clinical Success</b><br><br>Dr. Naveen Jain, Vice President, Biology R&D, Panacea Biotec, India   |
| 9.25 AM  | Reserved for Andreas Sjoelund, Global Product Manager, Bioprocess Downstream Hardware, Cytiva, Sweden  | <b>Optimizing Biologics Production: Strategies for Tech Transfer, Scaling Up, Collaboration, and Compliance</b><br>Xenia Sango, Chief Executive Officer & Managing Director, VivaZome Therapeutics, Australia  |   | <b>Shaping Clinical Trials- AI-Driven Optimisation</b><br>Chris Chong, Senior Director Clinical Services, Novotech, Australia  |
| 9.40 AM  |  |  |   | <b>Harnessing AI to Advance Biopharmaceutical Competitiveness and Innovation</b><br>Challenges in Drug development and Evolving role of Artificial Intelligence in BioPharma Industry<br>Josemund Menezes, Sr Industry Leader, Singapore |
| 9.50 AM  | <b>The BIOMANUFACTURING RENAISSANCE: Empowering Scientists with Multi-Compatible DSP Equipment</b><br>Rajkumar Gaikwad, Director, Bioengineering Business Unit, TruKing, India | <b>Innovative Facility Design and Next-Gen Biomanufacturing</b><br>Design and Technology of Modern Quality Premises for Biopharmaceutical Products<br>Hiroki Takamatsu, Executive Officer, VP, Quality Division, Kyowa Kirin Co., Ltd, Japan           | <b>Integrating Biologistics with AI and Blockchain: Pioneering the Future of Healthcare and Supply Chains</b><br>Douglas Amante, Senior Research, Singapore University of Technology and Design (SUTD), Singapore   |  |
| 10.05 AM |  |  |   | <b>Morning Tea Break, Exhibition Viewing, 1-1 Networking</b>   |
| 10.15 AM | Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking  | Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking  | <b>MORNING TEA BREAK, EXHIBITION &amp; POSTER PRESENTATION VIEWING, 1-1 NETWORKING</b>  |  |
| 10.20 AM |  |  |   |  |
| 10.50 AM |  |  |   |  |
| 11.00 AM | <b>Downstream Processing</b>   | <b>Innovative Facility Design and Next-Gen Biomanufacturing</b>  | <b>Roundtable Discussion: Challenges Faced in the Supply Chain</b>  | <b>De-Centralised and Multi-Centre Trials</b><br>Delivery of Clinical Trials to "Hard to Reach" Regional and Rural Communities in Australia  |

| Intensified and Continuous Processing |  |  |   |   |
|---------------------------------------|--|--|---|---|
|                                       | Intensifying Downstream Processing: The Role of Single-Use Systems (SUS)   | Smart Biomanufacturing: Navigating Industry 4.0 for Operational Excellence<br><br>Dhuha Abdul Aziz, Assistant Vice President for Manufacturing Industry 4.0, PT Biofarma, Indonesia                | <ul style="list-style-type: none"> <li>[Table 1] Licensing Agreements in Biotech: Dos and Don'ts<br/>Facilitator: <b>Bobby George</b>, VP, Group Head Regulatory Affairs, Reliance Life Sciences, India</li> <li>[Table 2] Intelligent Disruptions: Navigating the Waves of Artificial General Intelligence Innovation in Supply Chain Management<br/>Facilitator: <b>Douglas Amante</b>, Senior Research, Singapore University of Technology and Design (SUTD), Singapore</li> <li>[Table 3] Integrating Warehousing, Precision Packaging, and Last-Mile Assurance for Quality Product Delivery<br/>Facilitator: <b>Pankaj Thakur</b>, General Manager, Hetero, India</li> </ul> | Prof. Christopher Levi, Director Northern Cluster NSW regional rural and remote (R3) Clinical Trial Support Network and Executive Director Research and Innovation, Hunter New England Local Health District, Australia   |
| 11.25 AM                              |  | Next-Gen ADC Technologies<br>Conjugation methods, new targeted delivery and AI development   |   |   |
|                                       | Downstream Process Intensification: Strategies, Technologies and Tools<br><br>Anke Boerdgen, Head of Product Management, Chromatography Consumables, Sartorius, Germany                            | Development of AxcynDOT™ as a Next Generation ADC Payload Technology<br><br>Zou Bin, CEO & Founder, Axcynsis Therapeutics, Singapore   |   |   |
| 11.40 AM                              |  |  | Key Takeaway Sharing by the Roundtable Facilitator  | Revolutionising Clinical Trials: How Fenix- Pharmaron is Transforming Decentralised and Multi-site Research in Australia<br><br>Dr Esra Isikgel, Chief Executive Officer, Fenix Group, Head, Fenix - Pharmaron, Australia   |
| 11.50 AM                              | From Batch to Continuous Processes: Same Quality Attributes but with Better Economics<br><br>Alois Jungbauer, Professor, Institute of Bioprocess Science and Engineering, BOKU University, Austria | Discovery and preclinical validation of a novel enzyme cleavable linker for development of Next-Gen ADC against solid tumors<br><br>Dr. Mu Lin, Director of ADC Discovery, Nona Biosciences, China |   | Transforming Patient Participation and Data Collection in DCTs<br><br>Prof. Tam Nguyen, Deputy Director of Research, St Vincent's Hospital Melbourne, Australia   |
| 11.55 AM                              |  |  |   |   |
| 12.00 PM                              |  |  |   |   |
| 12.10 PM                              |  |  |   | Leadership Panel Discussion: Building an Interconnected Ecosystem for Global Clinical Trials<br><br>Moderator:<br><b>Josemund Menezes</b> , Sr Industry Leader, Singapore<br><br>Panelists:<br><ul style="list-style-type: none"> <li><b>Sachin Narkhede</b>, Senior Director Clinical Operations, Study Start-up APAC, ICON plc, Singapore</li> <li><b>Kunal Shah</b>, Head, Project Management, &amp; EARO Business Ops, EDDC, Singapore</li> <li><b>Prof. Tam Nguyen</b>, Deputy Director of Research, St Vincent's Hospital Melbourne, Australia</li> <li><b>Prof. Christopher Levi</b>, Director Northern Cluster NSW regional rural and remote (R3) Clinical Trial Support Network and Executive Director Research and Innovation, Hunter New England Local Health District, Australia</li> </ul> |
| 12.15 PM                              | Reserved for APAC CMO Showcase   | Reserved for APAC CMO Showcase   |   |   |
| 12.30 PM                              |  |  | Lunch, Exhibition & Poster Presentation Viewing   |   |
|                                       | Lunch Break, Exhibition Viewing & 1-1 Attendee Networking  | Lunch Break, Exhibition Viewing & 1-1 Attendee Networking  |   |   |
| 12.35 PM                              |  |  |   | Lunch, Exhibition Viewing, 1-1 Networking   |
| 1.40 PM                               |  |  | Global Packaging, Warehousing and Distribution Logistics Strategies   |   |

|         |   |  |   |   |
|---------|---|--|---|---|
|         |   |  | <p><b>Transformation of Global Artwork Work Process</b></p> <p><b>Shawn Lim</b>, Asia Artwork Mgmt + Lead of Strategic Projects, <b>Santen Pharmaceutical, Singapore</b></p>  |   |
| 2.10 PM |   |  | <p><b>Mitigating Risks, Theft, and Counterfeits in the Bio Supply Chain</b></p>   |   |
| 2.15 PM | <p><b>Downstream Processing</b><br/>Process Automation, Robustness and Monitoring</p>   | <p><b>Next-Gen ADC Technologies</b><br/>Conjugation methods, new targeted delivery and AI development</p>  | <p><b>Regulating Counterfeit Drugs: Strategies to Combat Spurious, Falsely Labeled, &amp; Falsified Pharmaceuticals</b></p> <p><b>Bobby George</b>, VP, Group Head Regulatory Affairs, <b>Reliance Life Sciences, India</b></p> |   |
| 2.20 PM | <p><b>From Insight to Action: Harnessing Regulatory / GxP Intelligence for Compliance and Risk Mitigation in Biologics Manufacturing</b></p> <p><b>Dinesh Khokal</b>, Global Director, Global Technical Operations, <b>Beigene, Singapore</b></p> | <p><b>The Future of Bioconjugates Therapeutics: Driving Innovation with the Next-Generation ADC Technology</b></p> <p><b>Paul Song</b>, Chief Scientific Officer, <b>GeneQuantum Healthcare, China</b></p>   |   | <p><b>Clinical Case Studies Update from Asian Biopharma</b></p>   |
| 2.40 PM |   | <p><b>Safety and Toxicity Management</b><br/>Optimizing ADC Safety and Efficacy: Off-target effects, pharmacokinetics, and patient safety</p>  |   | <p><b>Recent Advancements in Cell-Based Therapies: Insights and Innovations from Cytopeutics' Clinical Programs</b></p> <p><b>Prof. Chin Sze Piaw</b>, Co-Founder and CEO, <b>Cytopeutics, Malaysia</b></p> |
| 2.45 PM | <p><b>Emerging Alternatives to Chromatography in Downstream Processing</b></p>  | <p><b>Enhancing Therapeutic Window to Improve Efficacy and Minimize Off-Target Toxicity of ADCs</b></p> <p><b>Xueming Qian</b>, Founder, Chairman &amp; CEO, <b>Transcenta Holding Ltd, China</b></p>  | <p><b>Pharmaceutical Crime in the Post-Covid Era</b></p> <p><b>Ramesh Raj Kishore</b>, Regional Director - Asia Pacific, <b>Pharmaceutical Security Institute, Singapore</b></p>  | <p><b>Opportunities and Challenges in Clinical Trials for Rare Diseases in Asia Pacific</b></p> <p><b>Jing Ping Yeo</b>, Global Head, Project Operations, <b>George Clinical, Australia</b></p>             |
| 3.00 PM |   |  |   | <p><b>Early Phase Clinical Trial Capabilities in NSW</b></p>  |
| 3.05 PM | <p><b>Key Quality Standards in Downstream Biological Manufacturing</b></p>  | <p><b>Panel Discussion: Translational Strategies in PK/PD: Ensuring Success in Early Clinical Development</b></p>  |   | <p><b>Sook Wern Chua</b>, Head of Operational Strategy, <b>Scientia Clinical Research, Australia</b></p>  |
| 3.10 PM |   |  |   |   |
| 3.15 PM | <p><b>Butet Manurung</b>, Director, Factory, <b>Daewoong Biologics, Indonesia</b></p>   | <p>Moderator:<br/><b>Dr. John Luk</b>, Chairman &amp; Founder, <b>Arbele Bio, USA</b></p> <p>Panelist:</p> <ul style="list-style-type: none"> <li><b>Janise Chevrier-Lee</b>, Regional Medical Director, Oncology, <b>International Markets and Greater China, Astellas, Singapore</b></li> <li><b>Paul Song</b>, Chief Scientific Officer, <b>GeneQuantum Healthcare, China</b></li> <li><b>Simon Shih-Hsien Chuang</b>, CEO, <b>Honeybear Biosciences, Taiwan</b></li> </ul> | <p><b>Afternoon Break, Exhibition &amp; Poster Presentation Viewing</b></p>   | <p><b>An Industry Perspective of Drug Development in Emerging Countries</b></p> <p><b>Ivan Horak</b>, CEO and Founder, <b>Tikva Allocell, Singapore</b></p>   |
| 3.30 PM |   |  |   |   |
| 3.40 PM | <p><b>Afternoon Tea Break, Exhibition Viewing &amp; 1-1 Attendee Networking</b></p>   | <p><b>Afternoon Tea Break, Exhibition Viewing &amp; 1-1 Attendee Networking</b></p>  |   |   |
| 3.50 PM |   |  | <p><b>Mitigating Risks, Theft, and Counterfeits in the Bio Supply Chain</b></p>   | <p><b>Afternoon Tea Break, Exhibition Viewing, 1-1 Networking</b></p>   |

|         |   |  |  |
|---------|---|--|--|
| 4.15 PM | <p><b>Plenary Session: The Next Big Steps for Biomanufacturing Success</b></p> <p><b>Regional Collaboration on Vaccine Manufacturing Capacity</b></p> <p>Dr. Nakorn Premsri, Director, National Vaccine Institute, Thailand</p> | <p><b>How Can You Learn from Cross-Industry Supply Chain and Logistics Management to Improve Efficiency and Cost Management?</b></p> <p>Arani Chatterjee, Joint President, Cadila Pharmaceuticals, India</p> |  |
| 4.20 PM |   | <p><b>Combatting Counterfeiting: Insights from a Customs Perspective</b></p>   | <p>Oncology Clinical Trials: New Modalities and Industry Innovations</p>   |
| 4.25 PM |   |  | <p><b>Adoption of Next-Generation Sequencing (NGS) in Oncology Trials (tbc)</b></p> <p>Dr. Nitu Sinha, Vice President and Head of Pharmacovigilance, Mankind Pharma, India</p> |
| 4.40 PM | <p><b>Panel Talk: From Vision to Reality: What's Next for Biomanufacturing's Breakthroughs?</b></p>   |  |  |
| 4.50 PM |   |  | <p><b>Reserved for Solution/Service Provider</b></p>   |
| 5.05 PM |   |  | <p><b>Oncology Trials with Biosimilars: Challenges and Updates</b></p>   |
| 5.10 PM | <p><b>Chairperson Closing Remarks</b></p>   | <p>Chairperson Closing Remarks, End Of Conference Day 2</p>  | <p>Dr. Shubhadeep Sinha, Senior Vice President, Global Head-CD&amp;MA, Hetero Group of Pharmaceutical Companies, India</p>   |
| 5.20 PM | <p><b>End of Conference Day 2</b></p>   |  |  |
| 5.30 PM |   |  | <p><b>End of Conference Day 2</b></p>  |